story of the week
Paclitaxel–Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
J. Clin. Oncol 2020 Oct 23;[EPub Ahead of Print], A Fernandez-Martinez, IE Krop, DW Hillman, MY Polley, JS Parker, L Huebner, KA Hoadley, J Shepherd, S Tolaney, NL Henry, C Dang, L Harris, D Berry, O Hahn, C Hudis, E Winer, A Partridge, CM Perou, LA CareyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.